Sagimet Biosciences Inc.
Sagimet Biosciences Inc.
Your view on SGMT
Overview
What the company does, where it operates, and who runs it.
About Sagimet Biosciences Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- David A. Happel
- Headquarters
- 155 Bovet Road, San Mateo, CA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- David A. Happel
- Headquarters
- 155 Bovet Road, San Mateo, CA, US
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne.
The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Sagimet Biosciences Inc., and the rating behind it. SGMT last traded at $10.88; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Sagimet Biosciences Inc.. Starting points for Sagimet Biosciences Inc.: EPS -$0.89, beta 3.49 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Sagimet Biosciences Inc.. Sagimet Biosciences Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Sagimet Biosciences Inc.. Trailing twelve-month EPS for Sagimet Biosciences Inc. stands at -$0.89. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Sagimet Biosciences Inc.. Sagimet Biosciences Inc. has reported as a listed company since 2023. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Sagimet Biosciences Inc. valued side by side against its closest peers. Sagimet Biosciences Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Sagimet Biosciences Inc., and how their positions are changing. At a $354.5M market value, institutional positions materially move Sagimet Biosciences Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Sagimet Biosciences Inc. executives and directors. Shares of Sagimet Biosciences Inc. have traded between $1.73 and $11.41 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Sagimet Biosciences Inc.. Sagimet Biosciences Inc. is a $354.5M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Sagimet Biosciences Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Sagimet Biosciences Inc.. Coverage tracks Sagimet Biosciences Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.